参考资料 [1]Jonathan Spicer. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo)vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. https://meetings.asco.org/2024-asco-annual-meeting/15...
In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' ...
参考资料 [1]Jonathan Spicer. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. https://meetings.asco.org/2024-asco-annual-meeting/15777?presentation=232352%23232352...
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update 2021, ESMO Open Citation Excerpt : Ipilimumab induces de novo antitumor T-cell responses, including an increase in memory...
纳武利尤单抗联合含铂双药化疗 vs 化疗,对可切除NSCLC进行新辅助治疗:来自 CheckMate 816 的健康相关生活质量 (HRQoL) 结局 原标题:Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non...
PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Updatedoi:10.1016/j.jtho.2024.05.343Firas BadinDavid P. CarboneTudor-Eliade CiuleanuMichael SchenkerManuel Cobo-Dols...
CheckMate 816:纳武利尤单抗新辅助+铂类双药化疗(化疗)vs化疗在治疗可切除(IB-IIIA)非小细胞肺癌(NSCLC)上病理回归与无事件生存(EFS)的关系 Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for ...
Background Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free survival with nivolumab versus ipilimumab. This report provides...